StreetInsider.com News Articles

Lobe Sciences closes $2.1M private placement for sickle cell program

Thu, 20 Aug 2026 08:01:10 -0400

Lobe Sciences Ltd. (CSE: LOBE, OTCQB: LOBEF, Frankfurt: LOBE) has closed a non-brokered private placement, issuing 24,705,880 common shares at $0.085 per share for gross proceeds of approximately $2,100,000, according to a company statement.

The Vancouver-based clinical-stage biopharmaceutical company said proceeds will be used for working capital and general corporate purposes, with a portion directed to its wholly owned subsidiary, Applied Lipid Technologies, Inc., to advance its S-100 drug candidate for sickle cell disease toward human clinical trials. The company said it has already procured the active pharmaceutical ingredient required for those studies.

All securities issued under the placement are subject to

Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement

Thu, 20 Aug 2026 08:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

VANCOUVER, BC / ACCESS Newswire / August 20, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, is pleased to announce the closing of its previously announced non-brokered private placement offering of 24,705,880 common shares in the capital of the Company ("Common Shares") at a price of $0.085 per Common Share, for aggregate gross proceeds of approximately $2,100,000 (the "Private Placement").

The Company intends to use

Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement

Thu, 20 Aug 2026 08:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

The Company intends to use

Lobe Sciences Reports Third Quarter 2026 Financial Results

Tue, 18 Aug 2026 08:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / August 18, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, today announced its unaudited interim financial results for the third quarter of fiscal 2026 ended May 31, 2026 ("Q3 2026").

During the quarter, the Company continued to advance its development pipeline while maintaining a disciplined approach to capital allocation. Management believes the progress achieved in Q3 2026 reflects continued execution on its strategic priorities and reinforces the Company's focus on building long-term shareholder

Lobe Sciences Reports Third Quarter 2026 Financial Results

Tue, 18 Aug 2026 08:00:00 -0400

Lobe Sciences plans $2.1M private placement to fund S-100 development

Wed, 12 Aug 2026 08:46:11 -0400

Lobe Sciences Ltd. (CSE: LOBE, OTCQB: LOBEF, FSE: LOBE.F) announced a non-brokered private placement of 24,705,880 common shares at $0.085 per share, for aggregate gross proceeds of approximately $2,100,000.

According to a press release, the company intends to use the net proceeds to fund cash reserves, advance clinical development of the S-100 molecule being developed by its subsidiary Applied Lipid Technologies Inc., and for working capital and general corporate purposes.

S-100 is Applied Lipid Technologies' lead asset, currently targeting sickle cell disease as its initial indication. The company has stated it intends to evaluate S-100's potential eligibility for orphan-drug designation and for

Lobe Sciences Ltd. Announces Non-Brokered Private Placement

Wed, 12 Aug 2026 08:45:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

VANCOUVER, BC / ACCESS Newswire / August 12, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, is pleased to announce a non-brokered private placement offering of 24,705,880 common shares in the capital of the Company ("Common Shares") at a price of $0.085 per Common Share, for aggregate gross proceeds of approximately $2,100,000 (the "Private Placement").

The Company intends to use the net proceeds of the Private

Lobe Sciences Ltd. Announces Non-Brokered Private Placement

Wed, 12 Aug 2026 08:45:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

The Company intends to use the net proceeds of the Private

Lobe Sciences Announces Results of Annual General and Special Meeting of Shareholders

Wed, 05 Aug 2026 08:00:00 -0400

Shareholders Approve All Matters Presented at Meeting, Including New Long-Term Incentive Plan and Amendment to Constating Documents

VANCOUVER, BC / ACCESS Newswire / August 5, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, today announced the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held on July 30, 2026.

A total of 152,807,032 common shares were represented at the Meeting, representing approximately 49.6% of the Company's issued and outstanding common shares as of the June

Lobe Sciences Announces Results of Annual General and Special Meeting of Shareholders

Wed, 05 Aug 2026 08:00:00 -0400

Shareholders Approve All Matters Presented at Meeting, Including New Long-Term Incentive Plan and Amendment to Constating Documents

A total of 152,807,032 common shares were represented at the Meeting, representing approximately 49.6% of the Company's issued and outstanding common shares as of the June

Lobe Sciences Files Management Information Circular for Annual General and Special Meeting on July 30, 2026

Tue, 07 Jul 2026 06:00:00 -0400

The Company's Annual General and Special Meeting will be held on Thursday, July 30, 2026, at 11:00 a.m. (Vancouver time), at 15^th Floor, 1111 West Hastings Street, Vancouver, British Columbia, with virtual attendance available via Microsoft Teams
Dr. Frederick D. Sancilio, Executive Chairman and Chief Executive Officer, provided a letter to shareholders including an update on corporate strategy with a focus on uplisting to a senior exchange and an overview of progress across the Company's three subsidiary programs
Shareholders will be asked to vote on the election of directors, appointment of auditors, approval of a new

Lobe Sciences Files Management Information Circular for Annual General and Special Meeting on July 30, 2026

Tue, 07 Jul 2026 06:00:00 -0400

The Company's Annual General and Special Meeting will be held on Thursday, July 30, 2026, at 11:00 a.m. (Vancouver time), at 15^th Floor, 1111 West Hastings Street, Vancouver, British Columbia, with virtual attendance available via Microsoft Teams
Dr. Frederick D. Sancilio, Executive Chairman and Chief Executive Officer, provided a letter to shareholders including an update on corporate strategy with a focus on uplisting to a senior exchange and an overview of progress across the Company's three subsidiary programs
Shareholders will be asked to vote on the election of directors, appointment of auditors, approval of a new

Lobe Sciences Directors and Management Increase Equity Ownership Through Settlement of Accrued Fees by the Issuance of Common Shares

Tue, 09 Jun 2026 06:00:00 -0400

Directors and management elected to receive restricted equity in place of accrued fees payable, thereby increasing ownership and further aligning with shareholders
The Canadian Securities Exchange has accepted the share issuance, allowing the Company to complete the settlement
Company remains well-positioned with C$4.96 million in cash and short-term investments as of its most recent quarter ended February 28, 2026
Subsidiary R&D programs remain on track and on budget, with continued de-risking through Lobe's disciplined development model

VANCOUVER, BC / ACCESS Newswire / June 9, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F), a clinical-stage biopharmaceutical company advancing

Lobe Sciences Directors and Management Increase Equity Ownership Through Settlement of Accrued Fees by the Issuance of Common Shares

Tue, 09 Jun 2026 06:00:00 -0400

Directors and management elected to receive restricted equity in place of accrued fees payable, thereby increasing ownership and further aligning with shareholders
The Canadian Securities Exchange has accepted the share issuance, allowing the Company to complete the settlement
Company remains well-positioned with C$4.96 million in cash and short-term investments as of its most recent quarter ended February 28, 2026
Subsidiary R&D programs remain on track and on budget, with continued de-risking through Lobe's disciplined development model

VANCOUVER, BC / ACCESS Newswire / June 9, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F), a clinical-stage biopharmaceutical company advancing

Lobe Sciences Announces Proposed Shares for Debt Transaction

Mon, 01 Jun 2026 22:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / June 1, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates for diseases with significant unmet medical needs, under a disciplined, pharmaceutical development platform, progressing assets from early development to clinical stages, through focused subsidiary companies, today announced that it has entered into agreements to settle C$1,372,761.20 in outstanding management and director fee debt through the issuance of an aggregate of 12,749,643 common shares of the Company (the "Settlement Shares") at a price of $0.11 per Settlement Share (the "Debt

Lobe Sciences Announces Proposed Shares for Debt Transaction

Mon, 01 Jun 2026 22:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / June 1, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates for diseases with significant unmet medical needs, under a disciplined, pharmaceutical development platform, progressing assets from early development to clinical stages, through focused subsidiary companies, today announced that it has entered into agreements to settle C$1,372,761.20 in outstanding management and director fee debt through the issuance of an aggregate of 12,749,643 common shares of the Company (the "Settlement Shares") at a price of $0.11 per Settlement Share (the "Debt

Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York

Wed, 06 May 2026 20:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. ("Lobe", or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates through a disciplined pharmaceutical development platform, progressing assets from early development to the clinic through focused subsidiary companies, today announced that its Chief Executive Officer, Dr. Frederick D. Sancilio, will be attending the D. Boral Capital Global Conference being held on May 7, 2026 at The Plaza Hotel in New York City.
Dr. Sancilio will be available for meetings with institutional investors, pharmaceutical companies, and potential

Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York

Wed, 06 May 2026 20:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. ("Lobe", or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates through a disciplined pharmaceutical development platform, progressing assets from early development to the clinic through focused subsidiary companies, today announced that its Chief Executive Officer, Dr. Frederick D. Sancilio, will be attending the D. Boral Capital Global Conference being held on May 7, 2026 at The Plaza Hotel in New York City.
Dr. Sancilio will be available for meetings with institutional investors, pharmaceutical companies, and potential

Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress

Wed, 06 May 2026 06:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates through a disciplined pharmaceutical development platform, progressing assets from early development to the clinic through focused subsidiary companies, today announced its unaudited interim financial results for the second quarter of fiscal 2026 ended February 28, 2026 ("Q2 2026") and provided an operational update.
During the quarter, the Company continued to advance its development pipeline while maintaining a disciplined approach to capital allocation. Management believes the progress achieved in Q2 2026

Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress

Wed, 06 May 2026 06:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates through a disciplined pharmaceutical development platform, progressing assets from early development to the clinic through focused subsidiary companies, today announced its unaudited interim financial results for the second quarter of fiscal 2026 ended February 28, 2026 ("Q2 2026") and provided an operational update.
During the quarter, the Company continued to advance its development pipeline while maintaining a disciplined approach to capital allocation. Management believes the progress achieved in Q2 2026

Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders

Thu, 23 Apr 2026 08:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / April 23, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company focused on advancing therapies for diseases with significant unmet medical needs, welcomes the recent White House Executive Order supporting the advancement of novel treatments for neurological and mental health disorders.
The Company believes the Executive Order represents an important step toward enabling scientific research in areas that have historically been difficult to study due to regulatory constraints. Lobe views this action as a meaningful shift toward allowing compounds to be

Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders

Thu, 23 Apr 2026 08:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / April 23, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company focused on advancing therapies for diseases with significant unmet medical needs, welcomes the recent White House Executive Order supporting the advancement of novel treatments for neurological and mental health disorders.
The Company believes the Executive Order represents an important step toward enabling scientific research in areas that have historically been difficult to study due to regulatory constraints. Lobe views this action as a meaningful shift toward allowing compounds to be

Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications Services

Tue, 21 Apr 2026 06:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / April 21, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE), a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs, is pleased to announce that it has engaged Massive Intelligence Pty Ltd ("Massive Intelligence") to provide investor relations and corporate communications services.
Pursuant to an engagement letter dated April 15^th 2026, the Company has retained Massive Intelligence for an initial term of three (3) months, commencing April 15, 2026, with the option to renew for a further

Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications Services

Tue, 21 Apr 2026 06:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / April 21, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE), a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs, is pleased to announce that it has engaged Massive Intelligence Pty Ltd ("Massive Intelligence") to provide investor relations and corporate communications services.
Pursuant to an engagement letter dated April 15^th 2026, the Company has retained Massive Intelligence for an initial term of three (3) months, commencing April 15, 2026, with the option to renew for a further

Lobe Sciences closes $950,000 private placement for drug development

Mon, 20 Apr 2026 06:04:36 -0400

Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) completed a non-brokered private placement offering of 14,615,384 common shares at $0.065 per share, raising approximately $950,000 in gross proceeds.

The biopharmaceutical company plans to use the funds for working capital and general corporate purposes, with a portion directed toward advancing its S-100 drug candidate for sickle cell disease treatment. Some proceeds will support its subsidiary, Applied Lipid Technologies, Inc., in developing the S-100 program toward human clinical trials.

The company stated it has obtained the active pharmaceutical ingredient required for the studies, allowing the program to proceed. Securities issued in the private placement are subject to a